{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-24-024574","form_type":"8-K","ticker":"RCKT","cik":"0001281895","company_name":"ROCKET PHARMACEUTICALS, INC.","filed_at":"2024-05-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:17.700434+00:00","generated_at":"2026-06-02T21:48:12.077351+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Rocket Pharma Q1 net loss $62.1M; cash $330.3M; EMA accepted MAA for FA, PDUFA date June 30 for LAD-I","bullets":["Net loss of $62.1M ($0.66/sh) vs $58.3M ($0.73/sh) in Q1 2023; G&A rose to $22.1M on commercial prep.","Cash and investments $330.3M as of March 31, 2024; expected operational runway into 2026.","EMA accepted MAA for RP-L102 (Fanconi Anemia); BLA submission to FDA expected H1 2024.","PDUFA date for KRESLADI (severe LAD-I) set for June 30, 2024; commercial preparations underway.","Appointed Aaron Ondrey as CFO and Meg Dodge as VP of Investor Relations & Corporate Communications."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-24-024574","json":"https://secwatch.observer/filing/0001140361-24-024574.json","markdown":"https://secwatch.observer/filing/0001140361-24-024574.md","text":"https://secwatch.observer/filing/0001140361-24-024574.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1281895/000114036124024574/0001140361-24-024574-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1281895/000114036124024574/ef20028575_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T21:48:12.077351+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2f80bc4d8a38294e786d852e0493c7d8fbd21843","claim":"ROCKET PHARMACEUTICALS, INC. reported preliminary financial results for the quarter ended March 31, 2024.","evidence_excerpt":"On May 6, 2024, Rocket Pharmaceuticals, Inc. (the “Company”) announced certain preliminary financial information for the quarter ended March 31, 2024.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1281895/000114036124024574/0001140361-24-024574-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2024"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}